FDA approves X4 Pharma's XOLREMDI for WHIM syndrome; pricing set at $496,400/yr

X4 Pharmaceuticals, Inc

XOLREMDI (mavorixafor) approved for WHIM syndrome patients aged 12+ to increase neutrophils and lymphocytes.
Wholesale acquisition cost: $496,400/yr (patients >50 kg, 400 mg daily) and $372,300/yr (≤50 kg, 300 mg daily).
Launch through specialty pharmacy PANTHERx Rare; X4Connect support program offers copay assistance and insurance help.
Corporate presentation posted on company website providing business updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.